GeoVax Labs (NASDAQ:GOVX) Stock Rating Upgraded by EF Hutton Acquisition Co. I

Posted by Patrick Bannon on Jul 24th, 2024

GeoVax Labs (NASDAQ:GOVX – Get Free Report) was upgraded by stock analysts at EF Hutton Acquisition Co. I to a “strong-buy” rating in a research report issued on Tuesday, Zacks.com reports.

A number of other research analysts also recently issued reports on GOVX. HC Wainwright restated a “buy” rating and set a $8.00 target price on shares of GeoVax Labs in a research report on Tuesday, July 2nd. Roth Mkm initiated coverage on shares of GeoVax Labs in a research report on Tuesday, July 16th. They set a “buy” rating and a $20.00 target price on the stock. Finally, Roth Capital upgraded shares of GeoVax Labs to a “strong-buy” rating in a research report on Tuesday, July 16th.

Check Out Our Latest Stock Analysis on GOVX

GeoVax Labs Trading Down 2.3 %

Shares of NASDAQ GOVX opened at $2.58 on Tuesday. The firm’s 50-day simple moving average is $2.23 and its 200 day simple moving average is $2.42. GeoVax Labs has a 12-month low of $1.09 and a 12-month high of $9.75.

GeoVax Labs (NASDAQ:GOVX – Get Free Report) last issued its quarterly earnings results on Tuesday, May 14th. The company reported ($2.47) earnings per share (EPS) for the quarter. Research analysts expect that GeoVax Labs will post -7.41 EPS for the current fiscal year.

Hedge Funds Weigh In On GeoVax Labs

An institutional investor recently bought a new position in GeoVax Labs stock. Armistice Capital LLC purchased a new position in shares of GeoVax Labs, Inc. (NASDAQ:GOVX – Free Report) in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm purchased 1,626,516 shares of the company’s stock, valued at approximately $587,000. Armistice Capital LLC owned approximately 91.38% of GeoVax Labs as of its most recent SEC filing. Institutional investors own 6.09% of the company’s stock.

GeoVax Labs Company Profile

(Get Free Report)

GeoVax Labs, Inc, a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers.